Bio-implant Market Rising With Growth In New Technology Trends Research By 2026
The global bio-implant market size is expected to reach USD 102.7 billion by 2026, according to
a new report by Grand View Research., registering a 5.9% CAGR over the forecast
period. Rising adoption of bio-implants as a primary treatment for various
cardiovascular diseases (CVDs) like heart failure and Brady arrhythmias is the
major factor driving the market. According to a 2017 publication by the
American College of Cardiology (ACC), almost 200,000 pacemakers are implanted
in the U.S. every year. This can be attributed to increasing awareness
pertinent to cosmetic prostheses, coupled with technological advancements in
these prostheses.
With Covid-19 infections rising globally, the
apprehension regarding a shortage of essential life-saving devices and other
essential medical supplies in order to prevent the spread of this pandemic and
provide optimum care to the infected also widens. In addition, till a
pharmacological treatment is developed, ventilators act as a vital treatment
preference for the COVID-19 patients, who may require critical care. Moreover,
there is an urgent need for a rapid acceleration in the manufacturing process
for a wide range of test-kits (antibody tests, self-administered, and others).
The report will account for Covid19 as a key market contributor.
Bio-implants have been introduced to
cater to the rapidly growing requirement for replacing as well as assisting
natural tissue in the human body. For instance, in 2017, Stryker launched the
Mako total knee arthroplasty at the American Academy of Orthopedic Surgeons
(AAOS). The technology, coupled with the company’s implant, will provide
surgeons and patients a much improved implantation experience.
By product, the dental segment is
expected to grow at a lucrative rate, with increasing dental issues across the
globe aiding market growth. Apart from these, orthopedic implants and cardiac
pacemakers are in continuous demand due to growing prevalence of CVDs and
orthopedic conditions. According to WHO in a 2017 publication, almost 90% of
the people above the age of 40 years suffered from inflammatory and degenerative
diseases, leading to unbearable pain and immobility. This has upped demand for
spinal and other orthopedic implants.
To Request Sample Copy of this report, click the link:
Continuous technological innovations
in the field of implantable devices is set to drive the market for
bio-implants. MRI-enabled pacemakers, leadless pacemakers, and implantable loop
recorders are some of the most recent advancements in cardiovascular segments
by leading players. Major companies
operating in this market include Medtronic; St Jude Medical (Abbott); Stryker;
DePuy Synthes; Zimmer Biomet; Organogenesis, Inc.; Arthrex, Inc.; Orthofix Holdings,
Inc.; Cochlear Ltd.; and Exactech, Inc.
Further key findings from the report suggest:
·
Orthopedic bio-implants emerged
as the largest revenue-generating segment in the market in 2018 owing to rising
application of the same in treatment of orthopedic injuries worldwide
·
Pacing devices accounted for
the leading revenue share within the cardiovascular bio-implants segment in
2018 owing to increasing affordability of patients and technological
advancements, such as MRI-proof pacemakers
·
Biomaterial metals accounted
for the dominant share in 2018 and is expected to maintain its lead throughout
the forecast period. High compatibility with the human body is the major factor
propelling the segment
·
North America led the global
market in 2018, mainly due to the presence of leading players in the region as
well as extensive research and development activities
·
Asia Pacific is expected to
grow at the highest pace during the study period owing to growing prevalence of
CVDs and orthopedic disorders, which can be attributed to unhealthy dietary
habits
·
Some of the major players are
Medtronic; St Jude Medical (Abbott); Stryker; DePuy Synthes; Zimmer Biomet;
Organogenesis, Inc.; Arthrex, Inc.; Orthofix Holdings, Inc.; Cochlear Ltd.; and
Exactech, Inc.
The
global bio-implant market size was estimated at USD 65.0 billion in 2018 and
will exhibit a CAGR of 5.9% during the forecast period. Rising adoption of
bio-implant procedures, over arthroscopy and other therapy treatments such as
physiotherapy, is a major factor driving the market. This preference is
attributed to associated benefits such as higher success rate and
biocompatibility. Other factors propelling the market include increasing
prevalence of cardiovascular diseases (CVD) and orthopedic ailments, large
geriatric population base, lifestyle changes, and rising adoption of cosmetic
surgeries.
The
market is also driven by rising awareness about cosmetic implants and
advancements in bioengineering technologies. Demand for non-surgical or
minimally invasive bio-implants is growing in numerous medical disciplines. For
instance, an increasing number of dental patients are choosing to opt for
bio-implants as an easier and more effective alternative to a root canal
procedure. Alarming increase in oral healthcare problems will further stimulate
demand for bio-implants. For instance, WHO’s 2016 Global Burden of Disease
Study (GBDS) estimated that oral diseases affected around half of the
population worldwide. Almost 3.58 billion people were known to be affected by
dental caries and various tooth problems. This will provide a wider addressable
market in the near future.
Sedentary lifestyle has been the
root cause of numerous chronic disorders such as CVD, congenital and
neuropathic disorders, and osteoarthritis. This has propelled the demand for
bio-implants across the globe. For instance, according to the National Spinal
Cord Injury Statistical Center, almost 54.0% of the population in the U.S. was
suffering from spinal cord injury in 2016. These incidences are expected to
affect almost 60% of the U.S. population by 2020, resulting in growth
opportunities for the market.
Browse Press
Release of this report:
Grand View Research has segmented the
global bio-implant market on the basis of product, material, origin, end use:
Bio-implant Product Outlook (Revenue, USD Million, 2014 -
2026)
·
Cardiovascular
o Pacing Devices
o Pacemaker
o ICDs
o Stents
·
Dental
·
Orthopedic
o Orthobiologics
o Trauma
o Hip Replacements
o Knee Replacements
·
Ophthalmic
·
Spinal
·
Others
Bio-implant Material Outlook (Revenue, USD Million, 2014
- 2026)
·
Ceramics
·
Polymers
·
Alloys
·
Biomaterials
Bio-implant Origin Outlook (Revenue, USD Million, 2014 -
2026)
·
Autografts
·
Allografts
·
Xenografts
·
Synthetic
Bio-implant End Use Outlook (Revenue, USD Million, 2014 -
2026)
·
Hospitals
·
Clinics
·
Specialty Centers
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
Comments
Post a Comment